CATALYST: Mifepristone, HbA1c and Treatment Burden -- Clinical Evidence for Doctors

An HbA1c benefit is only one part of a clinical decision. This Hormone Insight evidence review examines the randomized treatment phase of CATALYST: mifepristone in selected adults with difficult-to-control type 2 diabetes and biochemical hypercortisolism.We review the population and trial design, the 24-week HbA1c and weight results, and findings on blood pressure, hypokalaemia, treatment discontinuation and serious adverse events. We also discuss missing data, secondary-endpoint multiplicity and why the result should not be generalized to everyone with type 2 diabetes.For doctors and healthcare professionals. Learning objectives: identify the selected population; distinguish the primary HbA1c result from secondary findings; interpret efficacy alongside tolerability, safety and missing-data limitations; and recognize the difference between trial eligibility and the licensed indication.Chapters00:00 Benefit and treatment burden00:23 The clinical question00:47 Cortisol biology01:10 Two study phases01:26 The selected population02:07 Intervention and comparator02:40 Endpoints and design03:13 HbA1c results04:06 Weight results04:31 Secondary-endpoint interpretation04:57 Blood pressure05:16 Hypokalaemia05:53 Treatment discontinuation06:25 Serious adverse events06:59 Euglycaemic ketoacidosis07:33 Adrenal insufficiency precautions07:54 Missing data and appraisal08:50 Long-term outcomes09:06 Clinical applicability09:45 Bottom line10:23 Sources and scopePrimary paper: DeFronzo et al. Diabetes Care. 2025;48(12):2036–2044. DOI: 10.2337/dc25-1055.PubMed: https://pubmed.ncbi.nlm.nih.gov/40550011/Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12635952/Korlym prescribing information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9Educational evidence appraisal, not patient-specific advice or a prescribing protocol. No CME accreditation is claimed. Narration is AI-generated using the Fahad voice. Study findings and prescribing information are distinct; consult current local product information before prescribing.